Last edition
News about "Gilles Rubinstenn"
ReST Therapeutics Receives US FDA IND Clearance for RST-101 in Early PTSD Treatment
ReST Therapeutics has received US FDA acceptance of its Investigational New Drug (IND) application for RST-101, enabling the initiation of a first-in-human clinical trial evaluating a novel early intervention approach for the treatment of post-traumatic stress disorder.
Gilles Rubinstenn | 29/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members